DISCLAIMER: This page is intended for members of the general public in Australia only.

The information provided on this site is intended for general information and education for Australia-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified Healthcare Professional.

Information about the NUVAXOVIDTM▼ (SARS-CoV-2 rS [NVX-CoV2373]) SUSPENSION FOR INJECTION

This vaccine has provisional registration in Australia for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older as a primary series, 2 dose course or as a booster dose in individuals 18 years of age and older, 6 months after the completion of a primary series. The use of this vaccine should be in accordance with official recommendations.

 

 

Important information

For more information about the NUVAXOVIDTM▼ (SARS-CoV-2 rS [NVX-CoV2373]) SUSPENSION FOR INJECTION , download the Consumer Medicines Information.

Consumer Medicines Information (CMI)
Learn More

Report an Adverse Event (AE)

To report any adverse events or side effects you can contact the Therapeutic Goods Administration (TGA) at www.tga.gov.au/reporting-adverse-events 

Alternatively, adverse events or side effects can be reported to Novavax Pharmacovigilance at +61 2 7202 1444 or via the Novavax Adverse Event Reporting Form.

Please do not report the same side effects to multiple systems as all reports will be shared between Novavax and TGA (in an anonymised form) and multiple reports will create unnecessary duplicates.

Contact Us

Tel: +61 2 7202 1444
09:00 - 17:00
Monday - Friday